Improved survival was seen in women with elevated body mass index versus men among patients newly diagnosed with multiple myeloma. Read More ›

Ciltacabtagene autoleucel shows benefit in patients with multiple myeloma who experience early relapse. Read More ›

Multiple Myeloma is a complex disease that can significantly affect the health-related quality of life of patients. These quality-of-life issues should be considered when assessing treatment patterns. Read More ›

The development of new treatments for multiple myeloma would benefit from a systematic consideration of patient preferences. Read More ›

A subgroup analysis looked at isatuximab plus lenalidomide-bortezomib-dexamethasone as first-line treatment in transplant-eligible newly diagnosed multiple myeloma patients with high-risk cytogenetics. Read More ›

Longer-term efficacy results with isatuximab in combination with carfilzomib and dexamethasone versus carfilzomib and dexamethasone alone in patients with relapsed/refractory multiple myeloma are promising. Read More ›

Teclistamab in combination with daratumumab may yield improved clinical efficacy in patients with relapsed/refractory multiple myeloma who are heavily pretreated per updated results from the TRIMM-2 trial. Read More ›

Patients with relapsed/refractory multiple myeloma were treated with subcutaneous isatuximab through an on-body delivery system—a wearable bolus injector that is attached to the patient’s abdomen. Read More ›

The past week in oncology-related news includes shortages of crucial pediatric cancer drug, results of a study of racial disparities in multiple myeloma, and new drug on the horizon for HER2 metastatic breast cancer. Read More ›

On September 26, 2019, the FDA approved daratumumab (Darzalex; Janssen) in combination with bortezomib, thalidomide, and dexamethasone for the treatment of newly diagnosed patients with multiple myeloma who are eligible for autologous stem-cell transplant (ASCT). The FDA granted this application priority review. Read More ›